I spent 3 days with pharma executives. They're suddenly taking longevity seriously.

For decades, "longevity" was a word serious drug makers avoided. It conjured images of supplement gurus, Silicon Valley biohackers, and anti-aging hucksters — not legitimate medicines backed by clinical trials.

The 2026 Aging Research and Drug Discovery (ARDD) meeting — the most important longevity conference of the year — landed in the US. After more than a decade in Europe, it was held in Boston, the center of the US biotech industry.

US regulators, executives from big pharma, and longevity upstarts came together for three days to discuss how drugs to combat age-related declines could become a reality, sooner rather than later. Executives from major drugmakers, including Pfizer, GSK, AstraZeneca, Novartis, and Eli Lilly, enthusiastically discussed their approach to "longevity drugs."

There was a breathlessness in the air, a can-you-believe-this tone from the longevity researchers who've spent their careers studying how we age, but hit a wall when it came to formulating actual therapies. Could their dreams of a future longevity pill be coming true?

A couple of years ago, scientists were still arguing over whether aging was a disease, and lamenting that the FDA didn't have an approval pathway built for them.

Now, they're starting to build the frameworks and discuss the data that the FDA will need to review to assess whether their longevity drugs can work. Here's what everyone was buzzing about on the ground.

Wealthy countries are going gray. Governments around the world are panicking, including in the US.

Add BI in Google so our reporting is easier to find when you’re searching for what matters.

"The basic idea is to move medicine away from asking 'what disease does this person have?' towards asking 'what is this person still capable of doing, and how do we measure it?'" said Andrew Brack, program manager for the federal government's $144 million healthy aging and longevity drug trial initiative, started in 2024, called PROactive Solutions for Prolonging Resilience (PROSPR).

Why chase fixes for diseases that develop through the course of decades, when you could use all those years to preserve health and function instead?

Until recently, we didn't have a good way to measure whether a drug was actually slowing down aging, in real time. New blood tests — often called biological age or organ "clocks" — are giving researchers a way to estimate whether someone's blood vessels, skin, heart, or entire body is aging slower or faster than expected.

There are also new genetic screening tools that can identify our unique vulnerabilities to diseases like Alzheimer's and sensitivities to different foods or medicines.